NSC 140873 （CAS No.:106410-13-3） is a potent inhibitor of the enzyme cytosolic phospholipase A2 (cPLA2)

NSC 140873（CAS No.: 106410-13-3） is a small molecule inhibitor that has been extensively studied for its potential therapeutic applications. It is also known as CAS No.: 106410-13-3. This compound is a potent inhibitor of the enzyme cytosolic phospholipase A2 (cPLA2), which plays a critical role in the release of arachidonic acid from phospholipids in cell membranes.

cPLA2 is an enzyme that is involved in the production of various inflammatory mediators, including prostaglandins, leukotrienes, and platelet-activating factors. Inhibition of this enzyme has been shown to reduce inflammation and pain, making NSC 140873 a promising therapeutic agent for the treatment of various inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel diseases.

NSC 140873 works by binding to the active site of cPLA2 and preventing the enzyme from cleaving phospholipids. This results in the reduction of arachidonic acid release and subsequent decrease in the production of inflammatory mediators. The inhibition of cPLA2 by NSC 140873 has been demonstrated in numerous preclinical studies, both in vitro and in vivo.

There is currently considerable interest in the development of cPLA2 inhibitors as potential therapeutic agents. Various small molecule inhibitors, including NSC 140873, have been investigated in preclinical studies. However, further research is needed to determine the efficacy and safety of these inhibitors in human clinical trials.

In conclusion, NSC 140873 is a promising cPLA2 inhibitor with potential therapeutic applications for the treatment of inflammatory diseases. Its inhibition of cPLA2 has been demonstrated in preclinical studies, and its development as a therapeutic agent warrants further investigation.

References:
1. Lio YC, Reynolds LJ, Balsinde J, Dennis EA. The mechanism of inhibition of cytosolic phospholipase A2 by aspirin in J774 macrophages. J Biol Chem. 1996;271(47):29208-29216.
2. Scruggs BS, Gilroy DW. Inflammatory lung injury: cPLA2 and beyond. J Lipid Res. 2019;60(3):467-472.
3. Melnikova I, Golden JB, Ambrus JL, et al. Cytosolic phospholipase A2 inhibition as a therapeutic target for inflammatory skin disease. Mol Med. 2014;20(1):435-446.